Loading…
Please register to continue your trial period!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
The initial therapeutic hypothesis underlying the anti-PD-1 /PD-L1 immune checkpoint blockade mechanism was built around the premise that it acts locally in the tumor, reversing the exhaustion of PD-1hi CD8+ T cells by “releasing the brakes.”
Immune-checkpoint inhibitors (ICI) are primarily effective in patients with immune-responsive tumors. Unfortunately, most patients with cancer either do not respond to Immune checkpoint inhibitors (ICIs) or experience disease progression after an initial response period.
Checkpoint inhibitors (CPIs) are usually ineffective in patients with [immune-cold](brain://F821zsN7Hk2RW-m-m9ql1A/CancerImmunotherapyImmunoOncologyColdT…